###### Significance Statement

The biological mechanisms of psychiatric disorders are still poorly understood, thereby hindering the development of mechanism-based novel therapies. Genetic variants, collectively termed copy number variants (CNVs), are robustly and reproducibly associated with many psychiatric disorders. For example, hemizygous deletions at the human chromosome 22q11.2 are associated with elevated rates of schizophrenia, autism, and intellectual disability; duplication at this locus is associated with autism and intellectual disability. Research in this area started to delve into the mechanistic bases of these CNVs. Studies using mouse models have identified several genes encoded on chromosome 22q11.2 (*Tbx1*, *Dgcr8*, *Comt*, *Sept5*, and *Prodh*) that directly contribute to certain aspects of autism and schizophrenia. The neuronal processes affected by these individual genes include adult neurogenesis, microRNA processing, catecholamine metabolism, and synaptic transmission. Understanding these potential mechanisms could help develop new therapies or drugs to better treat patients with psychiatric disorders.

Introduction {#s1}
============

Since the 1950s, psychopharmacology has drastically transformed the field of psychiatry. This transformation was not guided by a rational approach based on mechanistic knowledge; instead, many drugs were serendipitously identified to be beneficial for treating mental illness. Chlorpromazine was initially used as an anti-histamine drug to assuage low blood pressure and rapid heart rate during surgical shock; however, its antipsychotic effects were first recognized by Henri Laborit in 1952 and it was widely used for the treatment of schizophrenia by Pierre Deniker, Jean Delay, J. M. Harl, and Heinz Lehmann. Imipramine was initially developed by the pharmaceutical company Geigy as a chlorpromazine-like compound to combat psychosis of schizophrenia. Although imipramine did not achieve this intended effect, its beneficial effects on depression were recognized by Roland Kuhn in 1956. John Cade discovered the beneficial effects of lithium in patients with mania in 1949; this discovery was forgotten but was later recognized thanks to the work of Morgens Schou. The serendipitous discoveries of these drugs freed many patients from semi-permanent confinement in mental hospitals, which were often located in alienating remote locations, or from prolonged psychoanalysis treatment with little tangible improvement. Thus, these drugs and their sister compounds, which were subsequently developed, became a solid starting point to gain knowledge of their sites of actions, which provided valuable insights into the mechanisms underlying psychiatric disorders.

Nearly half a century later, we are witnessing yet another transformation in the field of psychiatry. Rapid advances in the field of genetics have identified cases of duplication and hemizygous deletions of chromosomal loci, collectively termed copy number variants (CNVs), which show a robust and reproducible association with a wide range of psychiatric disorders. CNVs provide new opportunities to explore the mechanisms underlying psychiatric disorders such as schizophrenia, autism spectrum disorder (ASD), bipolar disorder, intellectual disability (ID), and attention-deficit/hyperactivity disorder (ADHD).

CNVs {#s2}
----

CNVs are deletions and duplications of large stretches of chromosomes, which can extend up to a few million bases in length. In 2007 and 2008, a number of studies reported the association of many CNVs with schizophrenia and autism. Each CNV was found to have unprecedented levels of association with mental illness ([@CIT0134]; [@CIT0147]; [@CIT0150]; [@CIT0013]; [@CIT0018]; [@CIT0081]; [@CIT0084]; [@CIT0137]; [@CIT0142]; [@CIT0157]; [@CIT0164]). While several syndromic cases of developmental disorders had been known to be associated with copy number variations ([@CIT0076]), these studies presented a novel view that CNVs have a much broader contribution to nonsyndromic, as well as syndromic, cases of many psychiatric disorders.

Three features distinguish CNVs from widely studied common genetic variants such as single nucleotide polymorphisms (SNPs). First, CNVs are rare variants; each CNV is found in less than 1% of patients with schizophrenia or ASD ([@CIT0073]; [@CIT0118]). Second, unlike common variants (e.g., SNPs) that individually raise the risk for mental illness only slightly, the rates of psychiatric disorders among carriers of each CNV are extraordinarily high. The odds ratios for schizophrenia reach 67.7 with 22q11.2 deletions, 20.6 with 16p11.2 distal deletions, and higher than 10 with 2q16.3 deletions, 15q13.3 deletions, 7q11.23 duplications, 9p24.3 deletions/duplications, and 8q22.2 deletions ([@CIT0082]). Similarly, the odds ratios are high for ASD and ID with these and other CNVs ([@CIT0021]; [@CIT0047]; [@CIT0080]). Thirdly, each CNV is associated, to varying degrees, with multiple disorders such as schizophrenia, ASD, ID, bipolar disorder, depression, and ADHD ([@CIT0034]; [@CIT0080]; [@CIT0073]). The pleiotropic actions of CNVs do not conform to the existing clinical classification of psychiatric disorders, which is based on symptomatic clustering. However, the CNV effects are hardly surprising considering that the clinical diagnosis of one psychiatric disorder is often followed by another, even among idiopathic cases ([@CIT0112]).

Despite promising leads, the precise mechanistic links between CNVs and their symptomatic manifestations still remain poorly understood. In humans, analysis has been largely correlative. Due to technical limitations, studies have been unable to establish the causative effects of CNV-associated alterations in gene expression patterns and regional activity patterns in the brain with mental illness.

One way of viewing association is that all the genes encoded in a CNV contribute in some way to any given clinically defined psychiatric disorder. This could occur through the collective actions of all genes, particularly in the cases of large-sized CNVs. Consistent with this possibility, the severity of the phenotype increases with the size of the CNV and each of large de novo CNVs does not contain ASD-associated genes identified by exome sequencing ([@CIT0125]). An alternative view is that a single driver gene within a CNV is critical. This notion is supported by evidence that each of small de novo CNVs contained a single ASD-associated gene identified by exome sequencing, and no cases were found in which many such genes were encoded in a single small de novo CNV ([@CIT0125]). However, exome sequencing might not be ideal to identify driver genes if their variants detected by exome sequencing simply do not exist or do not frequently occur. Moreover, hemizygous deletion or duplication might produce more severe effects than some variants that exome sequencing identify. There are cases where a single gene can recapitulate the effects of a large deletion (e.g., 17p11.2) ([@CIT0076]). Thus, it is still possible that a larger size CNV increases the chances of affecting a few risk genes with large effects, and a small CNV contains more than one contributory gene.

Analyses of biological pathways have elegantly demonstrated select pathways in CNV cases in humans. However, some technical limitations need to be considered. First, some CNV-encoded genes are not listed in data sets for pathway analyses because their functions are not well characterized or they contribute to peripheral phenotypes and used as negative controls. Second, some analyses are done using all CNVs as a set. Such grouping is ideal to identify contributory genes and biological pathways common to all CNVs but not those unique to each CNV.

A third possibility is that more than one, but not all, gene in each CNV, regardless of its size, is contributory to psychiatric disorders. Consistent with this hypothesis, many genes known to be involved in diverse functions, such as synaptic functions and activity-regulated cytoskeleton-associated proteins, are represented in CNVs ([@CIT0157]; [@CIT0110]; [@CIT0015]; [@CIT0125]; [@CIT0082]). Data coming from mouse models lend further support for this hypothesis that several, but not all, genes even in a large CNV are contributory and the degree of contribution varies among such genes (see [Figure 1B--C](#F1){ref-type="fig"}) ([@CIT0062], [@CIT0064], [@CIT0061]; [@CIT0063]; [@CIT0095]; [@CIT0171]).

![22q11.2 CNVs and mouse models. (A) Human 22q11.2 hemizygous deletions and duplications associated with schizophrenia and autism spectrum disorder (ASD). The names of protein-coding genes only are provided for clarity. Color density increases with segment recurrence. Data were tallied from studies that examined schizophrenia and ASD patients with 22q11.2 CNV ([@CIT0147]; [@CIT0158]; [@CIT0081], [@CIT0082]; [@CIT0072]; [@CIT0109]; [@CIT0047]; [@CIT0124], [@CIT0125]; [@CIT0001]; [@CIT0146]; [@CIT0077]; [@CIT0117]; [@CIT0075]). The starting and ending addresses of deletions and duplications are based on the addresses indicated in their publications, but all addresses were converted into those of GRCh38.p12. (B) Mouse chromosome 16, a homolog of the minimal nested segment of human 22q11.2 CNV. (C) Mouse models of single gene deletions. Only those genes in which deletions were examined in congenic (10 or higher backcrosses) or co-isogenic mouse models were studied because biased genetic background in noncongenic mice results in interpretative difficulty ([@CIT0061]). Red indicates phenotypes consistent with 22q11.2 hemizygous deletions in humans. Black indicates no detectable effect. Purple indicates phenotypes opposite to those of human 22q11.2 deletion carriers. Anx, anxiety-related behaviors; PPI, prepulse inhibition; Pup, neonatal vocalization; SI, social interaction or sociability; Voc Adult, adult vocalization; WM, working memory. Neonatal vocalization was recorded on and before neonatal day 12 under maternal separation, which reflects ASD-related pup social communication with a mother ([@CIT0148]; [@CIT0037]; [@CIT0071]; [@CIT0096]). Adult vocalization was recorded at 9 weeks of age in a view jar, arena, click box, geotaxis grid, and tube and collectively analyzed. Adult vocalization could reflect an adverse reaction to stress or expressions of anxiety. As no second mouse was present in any of the experimental settings, it does not reflect interactive social behavior. Please note that the data presented here are based on information available as of April 2, 2019. We set a lenient significance level at *P *\< .05. Readers are advised to check the site for updates at [http://www.mousephenotype.org/](http://www.mousephenotype.org/phenoview/). *Prodh* ([@CIT0107]; [@CIT0074]); *Dgcr2* ([@CIT0074]); *Slc25a1* ([@CIT0074]); *Mrpl40* ([@CIT0028]); *Sept5* ([@CIT0058]; [@CIT0062]; [@CIT0074]); *Gp1bβ* ([@CIT0074]); *Tbx1* ([@CIT0060]; [@CIT0148]); *Comt* ([@CIT0105]; [@CIT0100], [@CIT0101]; [@CIT0074]); *Tango2* ([@CIT0074]); *Dgcr8* ([@CIT0040]; [@CIT0102]; [@CIT0020]); *Ranbp1* ([@CIT0074]); *Rtn4r* ([@CIT0074]).](pyz026f0001){#F1}

22q11.2 CNV {#s3}
-----------

Unlike most CNVs that were more recently discovered in 2007 and 2008, the association between several CNVs and syndromic developmental disorders was known much earlier ([@CIT0076]). Robert Shprintzen and his colleagues at the Albert Einstein College of Medicine and the Montefiore Hospital were following up on patients exhibiting a cluster of physical symptoms including cleft palate, congenital heart defects, characteristic facial features, and learning disability ([@CIT0138]). They were found to have high rates of ID and delays in cognitive and language development ([@CIT0051]). In 1992, Shprintzen and colleagues reported that some of those patients also suffered from schizophrenia ([@CIT0139]). In the same year, several research teams, including Shprintzen's, reported that the patients exhibiting the above-mentioned physical abnormalities carried deletions at chromosome 22q11.2 ([@CIT0031]; [@CIT0127]). Together, these data established both an association between schizophrenia/learning disability and the physical symptoms, and an association between the physical symptoms and 22q11.2 hemizygous deletions. Since then, the direct association of 22q11.2 deletions with schizophrenia, learning disability, ID, anxiety, and ADHD has been consistently replicated by his group and others ([@CIT0049]; [@CIT0017]; [@CIT0068]; [@CIT0078]; [@CIT0083]; [@CIT0090]; [@CIT0143]).

Although early estimates were confounded by small sample sizes and ascertainment biases, current estimates, which are based on large sample sizes, indicate that 22q11.2 deletions occur at the rate of approximately 0.3% in general schizophrenia samples ([@CIT0073]; [@CIT0118]; [@CIT0082]). Conversely, among carriers of 22q11.2 deletions, 30% of the adults develop schizophrenia ([@CIT0131]), 13% to 27% are diagnosed with ASD depending on their age, 16% to 36% are diagnosed with ADHD, and 24% to 36% are diagnosed with anxiety ([@CIT0093]; [@CIT0041]; [@CIT0004]; [@CIT0069]; [@CIT0131]; [@CIT0159]; [@CIT0066]).

One important detail for consideration is that the cohorts of patients with schizophrenia used in large-scale studies and meta-analyses do not systematically include or exclude patients with ID diagnoses. Some cohorts were formed using inpatient samples that included patients with low IQ, and other cohorts may have excluded patients with ID. The exclusion of the ID comorbidity from schizophrenia samples is expected to underestimate the actual rate of such CNVs in schizophrenia, as almost half of the patients with 22q11.2 deletion are diagnosed with ID.

Duplication of 22q11.2 was also identified by a team of researchers at the Albert Einstein College of Medicine ([@CIT0033]). Many cases of 22q11.2 duplication were shown to exhibit epilepsy, ID, ADHD, and ASD ([@CIT0036]; [@CIT0059]; [@CIT0114], [@CIT0113]; [@CIT0168]; [@CIT0026]; [@CIT0002]; [@CIT0035]; [@CIT0089]; [@CIT0149]; [@CIT0027]; [@CIT0115]; [@CIT0160]; [@CIT0169]; [@CIT0079]; [@CIT0141]; [@CIT0159]) at rates higher than those of noncarriers ([@CIT0066]; [@CIT0099]). Schizophrenia samples have shown lower rates of 22q11.2 duplication compared with controls; therefore, this variant is considered to be a protective factor ([@CIT0116]). However, a recent study with a larger sample size did not find this effect to be statistically significant after genome-wide correction ([@CIT0082]). Additional cases of schizophrenia, psychosis, paranoia, hallucination, suicidal ideation, and mood disorders among 22q11.2 duplication carriers have also been reported (van [@CIT0003]; [@CIT0099]; [@CIT0161]). Again, interpretation of these results should also consider how the samples were collected, as most duplication carriers have cognitive deficits and many are diagnosed with ID.

There are some individual variations in the locations and sizes of 22q11.2 duplication and hemizygous deletions. The majority of 22q11.2 deletions are approximately 3.0 Mb in size, but there are nested cases of 2.0-Mb or 1.5-Mb deletions and duplications; nested 1.5-Mb deletions help narrow down critical regions within the larger deletions (see [Figure 1A](#F1){ref-type="fig"}).

Because the smallest nested deletion is still 1.5 Mb long, it is not possible to analyze how each 22q11.2 gene contributes to the symptoms of psychiatric disorders in humans. While there are individual cases of much smaller deletions ([@CIT0047]), they are too few to statistically determine the definitive role of the encoded genes in mental illness. Researchers have attempted to correlate SNPs of some individual 22q11.2-encoded genes with psychiatric conditions in humans, but the results have been mixed and inconsistent, perhaps due to the weak effects of SNPs compared with deletions or duplications.

Predictive Power of Dimensions {#s4}
------------------------------

The presence of a CNV by itself is a reliable predictive risk factor for the onset of psychiatric disorders. However, penetrance of CNVs is incomplete, and additional predictors that signal the impending onset of psychiatric disorders are needed. The underlying impetus to identify such predictors is that they might serve not only as a warning signal but also as a good starting point for early intervention. Moreover, identifying the mechanisms underlying those predictors may allow preventive therapeutic options to be used long before the onset of psychiatric disorders.

There are some known factors that predict the future onset of psychiatric disorders ([@CIT0103]). Typically, ASD is clinically diagnosed in children when they are 2 to 3 years of age. However, certain prognostic features, such as reduced eye contact ([@CIT0176]) and atypical preverbal vocalizations ([@CIT0037]), could signal the future onset of ASD at least in a subpopulation ([@CIT0173]; [@CIT0038]; [@CIT0104]). Atypical cries do not optimally facilitate bonding or reciprocity between babies and mothers because the emotional state of such atypical cries is not easily understood ([@CIT0175]) or is negatively perceived ([@CIT0174]) by mothers. Delayed motor and language development ([@CIT0177], [@CIT0103]) are also noted among incipient ASD babies; however, delayed motor development might not be specific to ASD, as it is also seen in children with other developmental issues ([@CIT0067]).

Individuals who develop schizophrenia after adolescence show atypical developmental trajectories in some domains before symptoms reach diagnostic thresholds. School performance, behavioral development, and various cognitive capacities, particularly complex cognition and social cognition, start to precipitously lag behind their peers 10 years before the onset of psychosis ([@CIT0153]; [@CIT0151]; [@CIT0056]). Children and adolescents who later develop schizophrenia lag in working memory, attention, and processing speed ([@CIT0024]; [@CIT0025]; [@CIT0044]; [@CIT0163]; [@CIT0119]; [@CIT0011]; [@CIT0085]; [@CIT0012]; [@CIT0135]). Cognitive deficits in individuals with schizophrenia have been shown to affect a wide range of capacities, including attention, working memory, executive function, episodic memory, semantic memory, visual memory, verbal ability and learning, spatial memory and reasoning, face memory, emotion differentiation, verbal reasoning, list memory, processing speed, and fluency ([@CIT0126]; [@CIT0170]; [@CIT0042]; [@CIT0111]; [@CIT0050]; [@CIT0130]; [@CIT0154]).

Evidence from 22q11.2 deletion cases is consistent with this line of evidence obtained from idiopathic cases. The most profoundly impaired capacities are facial memory, identification of emotions from facial expressions, emotion intensity differentiation, and age differentiation of faces; other capacities are also impaired, including executive functions, verbal and spatial memory, verbal and nonverbal reasoning, and spatial reasoning. A delay in the developmental maturation of most of these features can be seen as early as 8 years of age among 22q11.2 deletion carriers compared with individuals with developmental delays or typically developing individuals ([@CIT0057]). In particular, some carriers of 22q11.2 deletions show a decline in IQ scores from childhood to adulthood, and the degree of this decline predicts the subsequent onset of psychosis ([@CIT0053], [@CIT0054]; [@CIT0155]).

Modeling CNVs {#s5}
-------------

Model organisms complement human studies because specific genes or small chromosomal segments within a CNV can be isolated and the actual functional impact of their dose alterations on central nervous system functions and behaviors can be evaluated, which is not possible in humans. Moreover, the neuronal and molecular alterations caused by deletion or overexpression of each gene can be evaluated in model organisms. Worms, flies, fish, and mice have been used as models to identify the causal roles of genes in the manifestation of behavioral and neural phenotypes ([@CIT0055]). However, there are some limitations. First, homologs of many human 22q11.2 genes are not present in lower species. Many human 22q11.2 protein-coding gene and microRNA homologs are not present in flies and worms ([@CIT0055]). Second, relating genes to behaviors that are relevant to human psychiatric conditions is challenging in these organisms. The behavioral repertoire of worms, flies, and fish is limited, and higher-order cognitive functions that are affected in individuals with schizophrenia and ASD cannot be easily modeled. Third, there are obvious differences in the structure of the central nervous system between humans and flies, worms, and fish. Fourth, there are significant differences in the developmental stages between humans and those species.

Compared with those lower species, the murine and nonhuman primate models have fewer flaws. Many mouse models with large and small segmental deletions and duplication have been generated and tested. However, correlating behaviors to human psychiatric disorders is still challenging. There is no Diagnostic and Statistical Manual of Mental Disorders for mice or even nonhuman primates. There is no reliable or objective way to model hallucinations, delusion, and speech in mice or nonhuman primates. The anatomical basis for even more elemental cognitive functions (e.g., cognitive flexibility) might be different between humans and such model organisms; the degree of brain development is quantitatively and qualitatively different between humans and model organisms such as rodents and nonhuman primates ([@CIT0014]; [@CIT0136]; [@CIT0122]). Fundamental, motivational behaviors that are thought to occur across species show differences between species. Social behaviors in different species are based on different sensory cues---for example, smell and auditory cues in rodents vs visual and auditory cues in humans. Even nonhuman primates cannot completely overcome such limitations.

Nonetheless, some aspects or dimensions that are not necessarily specific to a disorder can be examined in both rodents and humans ([@CIT0088]). Mice exhibit certain behavioral dimensions that are thought to be relevant to human psychiatric conditions and are thus ideal for determining the genetic basis for those behaviors ([@CIT0062], [@CIT0064]; [@CIT0063]; [@CIT0095]; [@CIT0061]). For example, cognitive decline, including working memory deficits, is seen in patients with schizophrenia, ADHD, and ASD. Impaired social behaviors are seen, in various forms, in patients with ASD, schizophrenia, depression, and ADHD. Prepulse inhibition (PPI) is disrupted in patients with schizophrenia, obsessive compulsive disorder, and ADHD ([@CIT0046]). Examining such effects in mice may identify potential substrates involved in the causal relationship between CNVs and some aspects of psychiatric disorders ([@CIT0063]; [@CIT0095]; [@CIT0061]).

Don't Blame Behavior, Blame Experimental Designs {#s6}
------------------------------------------------

Variable or absent behavioral phenotypes have led some researchers to claim that mouse phenotypes, especially behavior, are inherently variable, and therefore neuronal and anatomical phenotypes should be used for analyzing the impact of genetic variants in mouse models. This misperception has arisen partly due to a lack of attention to the genetic background. Low reproducibility is not unique to behavioral phenotypes---anatomical, synaptic, molecular, and gene expression phenotypes are equally variable and not reproducible or interpretable in mutant models whose genetic background is not controlled.

When genetic background is systematically biased near the gene of interest in wild-type and mutant littermates, different mouse cohorts show varied degrees of such biases; so do independently developed mutant mouse lines of the gene. Such mutant and wild-type mice littermates do not share equally shuffled alleles near the deleted gene; more alleles of embryonic stem cells (many are of a 129 inbred mouse line) and of the breeder mice (often C57BL/6J), respectively, are present in mutant and wild-type littermates near the target gene because of lower recombination rates between that gene and nearby alleles compared with distant alleles ([@CIT0061]). In such mice or noncongenic mice, any phenotypic difference in behavior, anatomy, synaptic, and neurochemical functions or gene expression between wild-type and mutant mice cannot be attributed to the target gene ([@CIT0045]; [@CIT0162]; [@CIT0023]; [@CIT0172]; [@CIT0061]).

This point has been elegantly proven by a series of studies that have shown some reproducible phenotypic differences in gene expression patterns that can be truly attributed to the target gene when the genetic background is made increasingly homogeneous between mutant and wild-type littermates ([@CIT0152]; [@CIT0165]; [@CIT0121]; [@CIT0098]). Confounding gene expression alterations resulting from allelic differences between noncongenic mutant and wild-type mice are likely to impact other phenotypes, either independently or interactively with the target genes, as different inbred mouse lines have different baselines for the shape and volume of various anatomical structures ([@CIT0156]; [@CIT0016]; [@CIT0123]), the number of neurons ([@CIT0132], [@CIT0133]; [@CIT0070]; [@CIT0167]; [@CIT0123]), the shape and number of dendritic spines ([@CIT0120]), the degree of synaptic plasticity ([@CIT0091], [@CIT0092]; [@CIT0087]), and behavioral features including PPI ([@CIT0022]), working memory ([@CIT0022]), social behaviors ([@CIT0022]; [@CIT0039]), and neonatal vocalization ([@CIT0128], [@CIT0129]; [@CIT0039]). In fact, a behavioral phenotypic difference appears or disappears when the genetic background is altered by the type of inbred mice used ([@CIT0145]; [@CIT0062]).

One obvious solution to this problem is to make the genetic background homogeneous, as much as practically possible, by backcrossing a mutant to one inbred mouse line for over 10 generations (i.e., congenic mouse). Many well-designed studies have painstakingly developed congenic mutant mice. Although it is not possible to make the allelic differences between congenic mutant and wild-type littermates completely homogenous ([@CIT0010]; [@CIT0043]; [@CIT0061]), it still considerably reduces interpretative uncertainty. Another more fundamental approach is to generate a mutant mouse with embryonic stem cells derived from C57BL/6N mice and breed with C57BL/6N mice (co-isogenic mouse). The International Mouse Phenotyping Consortium (http://[www.mousephenotype.org/](http://www.mousephenotype.org/)) routinely generates and tests many co-isogenic mouse models for PPI and adult vocalization ([@CIT0074]). The use of co-isogenic mutant mice completely eliminates the confounding effects of systematic bias in allelic distributions near the target gene. Moreover, standardized behavioral assays are applied by the International Mouse Phenotyping Consortium, further increasing the level of reproducibility and interpretability.

Unfortunately, many studies have failed to reproduce original published results of noncongenic mutant mice. Some studies have indicated in vague terms that their mice are of "pure" C57BL/6J background or of "a C57BL/6J background." Often the cited references therein indicate that the original mice are noncongenic mice. Yet the authors do not elaborate on what is meant by "pure" and how "a C57BL/6J background" was achieved; technically, a completely homogenous genetic background---if that is meant by "pure"---is not possible when starting with noncongenic mice ([@CIT0010]; [@CIT0043]). Even when the data are reproducible in noncongenic mice, they might simply reflect the hard-to-break allelic differences near the target gene rather than the actual effects of target genes. Therefore, we will limit our discussion of mouse models to congenic or co-isogenic mice.

In Search of Individual 22q11.2 Driver Genes {#s7}
--------------------------------------------

Mouse models were developed to recapitulate the effects of human 22q11.2 duplications and deletions, small chromosomal segments, or individual genes on psychiatric disorders. We reported the first segmental duplication model of a 200-kb human chromosomal segment, which included human SEPT5, GP1BB, TBX1, and GNB1L ([@CIT0065]). This co-isogenic model was hyperactive, showed progressive exacerbation of hyperactivity in a stressful open field, and was unable to engage in reciprocal social interaction or building a nest. Satisfying predictive validity, 3 weeks of treatment with the antipsychotic drug clozapine attenuated the exacerbated, compulsive, and repetitive hyperactivity in these mice.

Our subsequent analysis focused on an adjacent approximately 190-kb human chromosomal segment, including TXNRD2, COMT, and ARVCF ([@CIT0144]). Congenic mice that overexpressed this segment were selectively impaired in the developmental maturation of working memory capacity from adolescence to adulthood; they were indistinguishable from wild-type littermates in acoustic PPI, reciprocal social interaction, or behaviors related to fear, anxiety, and mood. COMT, among the 3 encoded genes, is likely to be a contributory gene, as individuals with a high-activity allele of *COMT* show a blunted expansion of working memory capacity from adolescence to adulthood in humans ([@CIT0032]).

These 2 mouse models demonstrated that social/repetitive behaviors and developmental maturation of working memory are selectively impacted by high gene doses of the 200-kb and 190-kb chromosomal segments, respectively.

There are also mouse models of large hemizygous deletions of 22q11.2. A congenic *Dgcr2-Ufd1l* deletion model ([@CIT0019]) and a co-isogenic *Dgcr2-Hira* deletion model ([@CIT0029]) consistently showed defective acoustic PPI (see [Figure 1B](#F1){ref-type="fig"} for gene locations on the murine chromosome). A congenic *Dgcr2-Hira* deletion model ([@CIT0140]) and co-isogenic *Dgcr2-Hira* deletion model ([@CIT0094]) exhibited deficits in the acquisition phase of working memory.

Known biology guided early studies of single 22q11.2 driver genes, and genes of unknown functions were not examined. For example, early studies focused on the genes involved in synaptic transmission and metabolism of glutamate and dopamine because those neurotransmitters had been implicated in several psychiatric disorders. However, some results from those studies have been irreproducible partly because most studies used noncongenic mice. Moreover, known biology was also limited at that time. Since then, studies using congenic and co-isogenic mice have provided a wealth of reliable data, which have drastically revised our understanding of the contributions of individual 22q11.2-encoded genes to dimensional behaviors of psychiatric disorders, and new potential genes and neurobiological bases have emerged ([@CIT0064]; [@CIT0063]; [@CIT0095]; [@CIT0061]; [@CIT0171]).

The current mouse data do not support the view that all 22q11.2-encoded genes equally contribute to each dimension of mental illness (see [Figure 1C](#F1){ref-type="fig"}). For example, there are 22q11.2 genes that globally affect many dimensions of psychiatric disorders (e.g., *Tbx1*). Other genes are essential for a select set of behavioral dimensions (e.g., *Sept5*, *Dgcr8*, *Comt*, and *Prodh*). Deletions of many other 22q11.2 genes have not had an effect on the behavioral dimensions tested so far; however, a more extensive characterization of behavioral dimensions may reveal specific aspects relevant to mental illness that may be regulated by those genes ([@CIT0062], [@CIT0064], [@CIT0061]; [@CIT0063]; [@CIT0095]).

### Tbx1 {#s8}

*Tbx1* encodes a transcription factor and is 1 of the 4 protein-coding genes encoded in the 200-kb segment that we identified ([@CIT0065]). When compared with wild-type littermates, congenic *Tbx1* heterozygous mice scored lower in reciprocal social interaction and a working memory index and higher in anxiety-related behaviors. They also exhibited higher levels of an approach response to a nonsocial object at 2 months of age ([@CIT0060]). While cases of human Tbx1 mutations exist and are associated with ASD ([@CIT0052]; [@CIT0108]; [@CIT0097]), they carry additional mutations and other variants ([@CIT0097]); therefore, a causal role of TBX1 in ASD could not be definitively established. Our mouse studies complemented this limitation of the human studies.

Atypical behaviors in *Tbx1* heterozygous mice start to appear as early as on postnatal day 8. The sequence of vocal calls is altered in *Tbx1* heterozygous pups, which lowers the incentive for mothers to approach them ([@CIT0148]). In these mice, the atypical call sequence at the age of postnatal day 8 serves as a predictor for atypical social and cognitive dimensions at adolescence. This is consistent with the observations made in babies incipient for idiopathic ASD---those that were eventually diagnosed with ASD had emitted atypical cries ([@CIT0037]). As atypical cries among incipient ASD babies are often prognostic of the future outcome, such neonatal behavioral dimensions can be utilized to understand the mechanistic basis of the developmental trajectory of ASD ([@CIT0037]; [@CIT0071]; [@CIT0096]).

Adult neurogenesis has emerged as a potential mechanistic basis for low working memory capacity. Tbx1 protein expression is enriched in adult neural progenitor cells in the adolescent mouse brain ([@CIT0060]). When this gene is overexpressed in adult neural progenitor cells in the hippocampus, the mice exhibit a blunting of working memory capacity at 2 months of age; however, the same treatment has no detectable effect at 1 month of age ([@CIT0009]). These observations suggest that Tbx1 might impact the developmental maturation of working memory capacity via its effects on adult neurogenesis in 22q11.2 duplication cases. This might model the adult onset of working memory deficits seen in adult ASD patients, but it is unlikely that human *TBX1* plays a role in the early onset of cognitive impairments in patients with ID.

### Dgcr8 {#s9}

*Dgcr8* is another 22q11.2 gene that impacts more than one known dimension. Heterozygous mice are impaired in acoustic PPI, working memory, and spatial memory; however, anxiety-related behaviors are not affected. *Dgcr8* impact on social interaction has not been examined ([@CIT0040]; [@CIT0102]; [@CIT0020]). Potential mechanisms through which *Dgcr8* deficiency alters behavioral dimensions include adult neurogenesis ([@CIT0102]), disturbances in microRNA expression ([@CIT0040]; [@CIT0020]), short-term synaptic plasticity in the cortex ([@CIT0040]), and synaptic transmission of the thalamocortical projection ([@CIT0020]).

### Comt {#s10}

Although *Comt* is one of the 22q11.2 genes that is hemizygous in 22q11.2 deletion cases, heterozygous or homozygous deletion of this gene does not recapitulate the impacts of the whole genome deletion, suggesting that a low dose of *Comt* does not, by itself, contribute to the dimensions of 22q11.2 deletion cases. Homozygous deletion of *Comt* also has no effect on PPI ([@CIT0101]; [@CIT0074]). Neither homozygous nor heterozygous deletion of *Comt* affects sociability ([@CIT0100], [@CIT0101]). Heterozygous or homozygous deletion of *Comt* has no detrimental effect on working memory ([@CIT0105]; [@CIT0100]).

Our recent work implicates adult neurogenesis as a potential mechanism through which a high gene dose of *COMT* blunts the developmental maturation of working memory capacity at adolescence ([@CIT0144]; [@CIT0009]). This mechanism could be targeted for cognitive improvement in the duplication cases of 22q11.2. The methylating action of COMT on catecholamines and other catechol-carrying molecules might underlie this action of COMT overexpression on working memory.

### Sept5 {#s11}

Congenic *Sept5* homozygous mice have lower basal levels of social interaction compared with wild-type littermates ([@CIT0058]; [@CIT0062]). This observation is consistent with one reported case of *SEPT5* and *GP1BB* deletion with developmental delays ([@CIT0005]). Sept5 inhibits excess release of dopamine and glutamate and contributes to the formation of axonal and dendritic arborization ([@CIT0007], [@CIT0008]; [@CIT0030]; [@CIT0166]). However, social interaction is enhanced when Sept5 is overexpressed in the dorsal hippocampus and amygdala in mice ([@CIT0058]); this suggests that high doses of this gene, at least in these 2 structures, do not faithfully recapitulate 22q11.2 hemizygous deletion and duplication cases.

Genes encoding synaptic functions and activity-regulated cytoskeleton-associated proteins are considered to be functional categories for schizophrenia-associated CNVs ([@CIT0082]). SEPT5 is implicated in cytoskeletal organization and synaptic transmission ([@CIT0007]; [@CIT0166]) and is a component of the biological pathways of synaptic genes implicated in schizophrenia with CNVs ([@CIT0082]) and in 22q11.2 Gene Interaction Network and 22q11.2-linked pathway interactions ([@CIT0006]) in humans. However, homozygous or heterozygous deletion of *Sept5* in mice does not impair PPI, a sensorimotor gating dimension of schizophrenia ([@CIT0074]). Similarly, proteome analyses in humans with 22q11.2 hemizygosity identified SLC25A1 and its family members as critical for synaptic morphology and plasticity and mitochondrial functions ([@CIT0048]). However, deletions of these genes do not impair PPI in mice ([Figure 1](#F1){ref-type="fig"}) ([@CIT0074]). These observations in humans and mice may not be conflicting because PPI is just one dimensional aspect of schizophrenia and is not a proxy for clinically defined schizophrenia. Sept5 and SLC25A1 deficiency might have a rather selective effect on some unidentified behavioral dimensions in patients with schizophrenia.

When the genetic background of *Sept5* homozygous mice was experimentally altered using different inbred mouse lines, the degree of social interaction deficits changed ([@CIT0145]; [@CIT0058]; [@CIT0062]). Because of wide variations between individual SNPs in the genome, epistatic interactions between a CNV and SNPs outside or inside a CNV might phenotypically manifest differently among carriers. This may explain the diverse clinical diagnoses of the 22q11.2 CNV.

### Prodh {#s12}

Deletion of *Prodh* alone does not cause PPI deficits in a congenic genetic background ([@CIT0107]). Further, a co-isogenic *Prodh* mouse is normal in PPI ([@CIT0074]). Male co-isogenic *Prodh* homozygous mice exhibit atypical adult vocalization; female homozygous mice are normal ([@CIT0074]). Because adult vocalization was measured in many experimental settings such as open field, transparent tube, and cylinder and collectively analyzed in this assay, it is not clear whether such atypical vocalizations in males were an adverse reaction to stress or expressions of anxiety; it is not an expression of interactive social behavior, as no second mouse was present in any of the experimental settings.

Almost all genes encoded in the 22q11.2 CNV have some neuronal and molecular functions; however, mouse data indicate that not all encoded genes contribute to dimensions of psychiatric disorders. From a phenotypic perspective (see [Figure 1C](#F1){ref-type="fig"}), genes that have been found to reduce PPI include *Gp1bβ* and *Dgcr8*; PPI is not affected by the deletion of *Prodh*, *Dgcr2*, *Mrpl40*, *Sept5*, *Comt*, *Tango2*, *Ranbp1*, and *Rtn4r*. Working memory is negatively affected by the deletion of *Mpril40*, *Tbx1*, and *Dgcr8*; *Comt* deletion improves working memory. Sociability or reciprocal social interaction is reduced by the deletion of *Sept5* and *Tbx1*, but not by *Comt* deletion. Neonatal vocalization under a maternal separation test is negatively impacted by the heterozygous deletion of *Tbx1*. Adult vocalization under stress- or anxiety-provoking settings is reduced by the deletion of *Prodh*; the deletions of *Dgcr2*, *Slc25a1*, *Sept5*, *Gp1bβ*, *Comt*, *Tango2*, *Ranbp1*, and *Rtn4r* have no obvious effect. Anxiety-related behaviors are induced by the deletion of *Tbx1* but not by the deletion of *Sept5*, *Comt*, *or Dgcr8*.

There are 22q11.2 genes that induce robust anatomical abnormalities (e.g., *Dgcr2* and *Ranbp1*) ([@CIT0106]; [@CIT0086]) without affecting PPI or adult vocalization ([@CIT0074]). It is possible that the behavioral dimensions affected by such anatomical alterations have not yet been identified and examined. As more phenotypes are characterized, a more complete picture is likely to emerge. Nonetheless, neuronal, molecular, or gene expression phenotypes in the mouse brain should have an effect on behavioral dimensions before they can be safely considered as factors that contribute to the development of human psychiatric disorders ([@CIT0064]; [@CIT0063]; [@CIT0095]; [@CIT0061]).

Conclusions {#s13}
===========

CNVs have provided much hope for a deeper understanding of the mechanistic basis of mental illness. The pleiotropic actions of a CNV on many psychiatric disorders might challenge and revise the current paradigms of distinct psychiatric disorders. We are, however, still constrained by our limited technical capability to fully tap the potential of CNVs to improve our understanding of mental illness and develop better therapeutic options. Nonetheless, some hypotheses have emerged from mouse models of CNVs. An in-depth characterization of CNV-encoded genes in brain biology and their behavioral manifestation in mouse models is a prerequisite to reconstruct the precise functional gene-behavior relationship and to develop mechanism-based therapy for the various dimensional aspects of mental illness.
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